Sensible is pioneering the first cell-based platform for design, optimisation and manufacturing of pure, non-immunogenic, and highly functional mRNA to unlock the next generation of mRNA medicines. We partner on asset co-development with established pharmaceutical companies in the early stages of mRNA therapeutics development, adding value at each step of the process.